Litcius/Paper detail

COVID 19: Camostat and The Role of Serine Protease Entry Inhibitor TMPRSS2

Stefan Bittmann

2020Journal of Regenerative Biology and Medicine16 citationsDOI

Abstract

According to the latest research, the novel coronavirus uses the protein angiotensin-converting enzyme 2 (ACE-2) as a receptor for docking to the host cell. Essential for entry is the priming of the spike (S) protein of the virus by host cell proteases. A broadly based team led by infection biologists from the German Primate Centre and with the participation of the Charité Hospital in Berlin, the Hanover Veterinary University Foundation, the BG-UnfallklinikMurnau, the LMU Munich, the Robert Koch Institute and the German Centre for Infection Research wanted to find out how SARS-CoV-2 enters host cells and how this process can be blocked [1]. They have published their findings in the journal "Cell" [1]. The team of scientists was initially able to confirm that SARS-CoV-2 docks to the host cell via the ACE-2 receptor. They also identified Transmembrane serine protease 2 (TMPRSS2) as the cellular protein responsible for entry into the cell [1-3].

Topics & Concepts

TMPRSS2ProteasesSerine proteaseProteaseCoronavirus disease 2019 (COVID-19)Serine Proteinase InhibitorsBiologyTransmembrane proteinProtease inhibitor (pharmacology)ReceptorSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologySerineAngiotensin-converting enzyme 2CellEnzymeVirusBiochemistryMedicineInfectious disease (medical specialty)Internal medicineViral loadAntiretroviral therapyDiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19
COVID 19: Camostat and The Role of Serine Protease Entry Inhibitor TMPRSS2 | Litcius